Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07313410 · ClinicalTrials.gov registry record
Using Near-Infrared Light to Better Understand Peripheral Artery Disease
A clinical trial of Peripheral Artery Disease (PAD), sponsored by The University of Texas at Arlington.
- Recruiting
- Registry status
- 120
- Enrollment target
- 2
- Study locations
NCT07313410: Recruiting study of Peripheral Artery Disease (PAD), sponsored by The University of Texas at Arlington.
NCT07313410 is a study of Peripheral Artery Disease (PAD) that is actively recruiting participants, run by The University of Texas at Arlington. The registered enrollment target is 120 participants, below the 265-participant average among 5 other Peripheral Artery Disease (PAD) trials with a reported enrollment target (55% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07313410, a study of Peripheral Artery Disease (PAD), is actively recruiting participants, sponsored by The University of Texas at Arlington.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this study is to better understand how blood flows and how oxygen is utilized in the lower limbs of people who suffer from peripheral artery disease. This study will also assess how these factors affect treatment outcomes. Specific aims include: Aim 1: Utilize BB-NIR-DCS to differentiate PAD patients experiencing primary oxygen delivery limitations from those suffering from mitochondrial dysfunction. Aim 2: Test the efficacy of BB-NIR-DCS at predicting individual responses to vascular intervention.
Primary Outcome
Participants will complete a health questionnaire to gain a deeper understanding of their quality of life.
Conditions Studied
Study Locations (2)
Texas
- University of Texas at Arlington - Arlington
- University of Texas Arlington - Arlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-11-01 |
| Est. Completion | 2028-12-31 |
What NCT07313410 shows while recruiting
NCT07313410 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 265-participant average among 5 other Peripheral Artery Disease (PAD) trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Peripheral Artery Disease (PAD) appearing as the primary indexed condition, and to 0 interventions.
NCT07313410 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07313410 about?
NCT07313410 is a clinical study titled "Using Near-Infrared Light to Better Understand Peripheral Artery Disease". The goal of this study is to better understand how blood flows and how oxygen is utilized in the lower limbs of people who suffer from peripheral artery disease. This study will also assess how these factors affect treatment outcomes. Specific aims include: Aim 1: Utilize BB-NIR-DCS to differentia...
What is the current status of trial NCT07313410?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2025-11-01. Estimated completion is 2028-12-31.
What conditions does trial NCT07313410 study?
This clinical trial studies the following conditions: Peripheral Artery Disease (PAD).
Who is sponsoring clinical trial NCT07313410?
This trial is sponsored by The University of Texas at Arlington, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07313410 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Artery Disease (PAD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Serranator POINT FORCE Registry
RECRUITING
-
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
RECRUITING · Phase 2
-
Detecting Peripheral Artery Disease With the Pulse
RECRUITING · NA
-
The Chocolate Touch Study
ACTIVE NOT RECRUITING · NA
-
A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI